➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Express Scripts
McKesson
Boehringer Ingelheim
McKinsey

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

CHLORAMPHENICOL SODIUM SUCCINATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Chloramphenicol Sodium Succinate patents expire, and when can generic versions of Chloramphenicol Sodium Succinate launch?

Chloramphenicol Sodium Succinate is a drug marketed by Fresenius Kabi Usa and Gruppo Lepetit and is included in two NDAs.

The generic ingredient in CHLORAMPHENICOL SODIUM SUCCINATE is chloramphenicol sodium succinate. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the chloramphenicol sodium succinate profile page.

US ANDA Litigation and Generic Entry Outlook for Chloramphenicol Sodium Succinate

A generic version of CHLORAMPHENICOL SODIUM SUCCINATE was approved as chloramphenicol sodium succinate by FRESENIUS KABI USA on August 25th, 1982.

  Start Trial

Summary for CHLORAMPHENICOL SODIUM SUCCINATE
Drug patent expirations by year for CHLORAMPHENICOL SODIUM SUCCINATE
Pharmacology for CHLORAMPHENICOL SODIUM SUCCINATE

US Patents and Regulatory Information for CHLORAMPHENICOL SODIUM SUCCINATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa CHLORAMPHENICOL SODIUM SUCCINATE chloramphenicol sodium succinate INJECTABLE;INJECTION 062365-001 Aug 25, 1982 RX No Yes   Start Trial   Start Trial   Start Trial
Gruppo Lepetit CHLORAMPHENICOL SODIUM SUCCINATE chloramphenicol sodium succinate INJECTABLE;INJECTION 062278-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
AstraZeneca
Merck
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.